Hepatic decompensation in patients with HIV/Hepatitis B Virus (HBV)/Hepatitis C Virus (HCV) triple infection versus HIV/HCV coinfection and the effect of anti-HBV nucleos(t)ide therapy

Clin Infect Dis. 2014 Oct;59(7):1027-31. doi: 10.1093/cid/ciu476. Epub 2014 Jun 18.

Abstract

The incidence rate of hepatic decompensation was higher in patients with human immunodeficiency virus (HIV)/hepatitis B virus (HBV)/hepatitis C virus (HCV) triple infection than in those with HIV/HCV coinfection (24.1 vs 10.8 events per 1000 person-years; hazard ratio [HR], 1.89; 95% confidence interval [CI], 1.12-3.18). Compared with HIV/HCV-infected patients, the rate of decompensation was increased among HIV/HBV/HCV-infected patients receiving no anti-HBV therapy (HR, 2.48; 95% CI, 1.37-4.49) but not among those who did receive such therapy (HR, 1.09; 95% CI, .40-2.97).

Keywords: HIV; end-stage liver disease; hepatic decompensation; hepatitis B; hepatitis C.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / therapeutic use*
  • Cohort Studies
  • Coinfection / complications*
  • Coinfection / drug therapy
  • Female
  • HIV Infections / complications*
  • HIV Infections / drug therapy
  • Hepatitis B / complications
  • Hepatitis B / drug therapy
  • Hepatitis C / complications*
  • Hepatitis C / drug therapy
  • Humans
  • Incidence
  • Liver Failure / epidemiology*
  • Male
  • Middle Aged
  • Nucleotides / therapeutic use*
  • Retrospective Studies

Substances

  • Antiviral Agents
  • Nucleotides